secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001193125-26-100539
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS
--------------------------------------------------------------------------------

- Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.
- 79% achieved CR or CRi; 61% achieved CR; 55% of CR/CRi patients reached MRD-negative status.
- No cytokine release syndrome (CRS) observed; 35% of responders had high-risk TP53 mutation.
- Four patients proceeded to allogeneic stem cell transplant, a rare outcome in older/unfit patients.
- Data from RAINIER Phase 1b/2 trial and completed dose expansion trial support safety and tolerability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526100539/0001193125-26-100539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526100539/apvo-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-100539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer